Skip to main content
PEPTARA LABS
Get Started

Survodutide

Survodutide

Published by · Updated · How we research and check our pages

The short answer

Survodutide (research code BI 456906) is an investigational injectable that activates both the GLP-1 receptor and the glucagon receptor. It is in phase 3 development and is not an approved medicine.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What is survodutide?

Survodutide is an investigational peptide, coded BI 456906 in early research, that acts as a dual agonist at both the GLP-1 receptor and the glucagon receptor. It was developed as a long-acting subcutaneous injection and studied for weight management and metabolic liver disease. As of the most recent published trials, it remains in phase 3 development and has not been approved as a medicine (le Roux et al., 2024, PMID 38330987).

How does survodutide work?

Survodutide is a single molecule that switches on two receptors at once: the GLP-1 receptor, which lowers appetite and slows stomach emptying, and the glucagon receptor, which research links to higher energy expenditure and lower liver fat. Single-target GLP-1 agonists such as semaglutide produced about 15 percent mean weight loss in their trials (Wilding et al., 2021), and the design idea behind survodutide is that adding the glucagon arm may act on energy use and the liver as well as appetite. In its phase 2 obesity trial, the highest survodutide dose reached up to about 14.9 percent weight loss at 46 weeks (le Roux et al., 2024, PMID 38330987).

What does research report on survodutide for weight loss?

In a phase 2 randomized, placebo-controlled trial, adults with overweight or obesity in the highest survodutide dose group lost up to about 14.9 percent of body weight at 46 weeks, far more than placebo (le Roux et al., 2024, PMID 38330987). The trial enrolled 387 adults with a BMI of 27 or more and no diabetes at 43 centers in 12 countries; higher dose groups were associated with larger average weight reductions, and the placebo group changed by about 2.8 percent (le Roux et al., 2024, PMID 38330987). These are phase 2 findings, and phase 3 trials are the stage that would confirm longer-term results.

What does research report on survodutide for liver disease?

In a phase 2 trial in adults with MASH, a significantly larger share of survodutide participants had improvement in the disease without worsening of fibrosis than those on placebo: 62 percent in the top-performing dose group versus 14 percent on placebo (Sanyal et al., 2024, NEJM, NEJMoa2401755). MASH stands for metabolic dysfunction associated steatohepatitis, formerly called NASH, and it involves fat, inflammation, and scarring in the liver. The glucagon arm of survodutide is the reason researchers are testing it here, since glucagon receptor activation is associated with reduced liver fat. Confirmation in phase 3 is still pending.

How were the survodutide trials designed?

Both published phase 2 trials gave survodutide by subcutaneous injection and compared several dose groups with placebo (le Roux et al., 2024, PMID 38330987; Sanyal et al., 2024, NEJMoa2401755). The MASH trial enrolled 293 adults with biopsy-confirmed MASH and fibrosis stages F1 to F3 and ran 48 weeks; it also reported a liver fat drop of at least 30 percent in 57 to 67 percent of the survodutide groups, against 14 percent on placebo (Sanyal et al., 2024, NEJMoa2401755). The table lists the setting and what each trial reported, not the amounts.

Trial settingRouteReported outcomeSource
Phase 2, overweight or obesitySubcutaneous injectionUp to about 14.9% weight loss at 46 weeksle Roux et al., 2024, PMID 38330987
Phase 2, MASHSubcutaneous injectionMASH improvement without worsening of fibrosis in up to 62% vs 14% placeboSanyal et al., 2024, NEJMoa2401755

These results describe what the trials reported for groups of participants. Any personal decision, including eligibility, belongs to a qualified clinician.

How does survodutide compare with retatrutide and tirzepatide?

All three are multi-receptor metabolic agonists, but they target different receptor sets and have posted different peak weight-loss numbers in their trials.

CompoundReceptor targetsWeight loss reportedTrialStatus
SurvodutideGLP-1 plus glucagonUp to about 14.9% at 46 wkle Roux et al., 2024Investigational (phase 3)
TirzepatideGIP plus GLP-1Up to about 22.5%Jastreboff et al., 2022Approved for clinical use
RetatrutideGIP plus GLP-1 plus glucagonUp to about 24.2% at 48 wkJastreboff et al., 2023Investigational (phase 3)
SemaglutideGLP-1 onlyAbout 15% meanWilding et al., 2021Approved for clinical use

These numbers come from separate trials with different designs and populations, so they are not a head-to-head comparison. They show where each compound landed in its own study, not a guaranteed result for any person.

What side effects did survodutide research report?

The most common side effects in survodutide trials were gastrointestinal, especially nausea and vomiting, matching the known profile of the GLP-1 receptor class (le Roux et al., 2024, PMID 38330987). In the obesity trial, stomach and gut effects were reported in 75 percent of survodutide participants against 42 percent on placebo (le Roux et al., 2024, PMID 38330987), and the MASH trial reported nausea in 66 percent against 23 percent on placebo (Sanyal et al., 2024, NEJMoa2401755). Because survodutide also activates the glucagon receptor, trials monitored measures such as glucose and heart rate, and the full safety picture is still being characterized in phase 3.

Is survodutide approved or available?

No, survodutide is investigational and in phase 3 trials, so it has not been approved as a medicine, and any material is intended for laboratory research use only. It is not a treatment you can be prescribed as an approved product at this stage, and published data remain limited to phase 2 for both obesity and MASH (le Roux et al., 2024; Sanyal et al., 2024, NEJMoa2401755).

Survodutide: FAQ

Is survodutide the same as retatrutide?

No. Both include glucagon receptor activity, but retatrutide is a triple agonist that also hits the GIP receptor (Jastreboff et al., 2023), while survodutide is a dual GLP-1 plus glucagon agonist (le Roux et al., 2024).

What was survodutide called before?

It was coded BI 456906 in early research (le Roux et al., 2024, PMID 38330987).

How much weight did people lose on survodutide in the studies?

Up to about 14.9 percent of body weight at 46 weeks in the highest dose group of a phase 2 trial (le Roux et al., 2024, PMID 38330987).

How was survodutide given in trials?

As a subcutaneous injection, with participants randomly assigned to one of several dose groups or placebo (le Roux et al., 2024). This describes the trial design, not an instruction.

Does survodutide help fatty liver disease?

A phase 2 MASH trial reported disease improvement without worsening of fibrosis in up to 62 percent of a dose group versus 14 percent on placebo (Sanyal et al., 2024, NEJMoa2401755). Phase 3 data would be needed to confirm.

How does survodutide compare to tirzepatide?

They target different receptors, and survodutide's peak phase 2 weight loss (about 14.9 percent) was lower than tirzepatide's trial figure (up to about 22.5 percent), though the trials were separate (le Roux et al., 2024; Jastreboff et al., 2022).

Can I buy survodutide as a medicine?

No. It is investigational and not approved; any material is for laboratory research use only.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us